4D Molecular Therapeutics, Inc. (FDMT) Cash Flow Statement
4D Molecular Therapeutics, Inc. (FDMT) generated -$156.1M of operating cash flow over the twelve months to 2026-06-30, spent -$106000 on capital expenditure and had free cash flow of -$156.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FDMT4D Molecular Therapeutics, Inc.Follow FDMT — free
—
Price chart with a free account
- Market cap
- 779.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -50.9 | -69.1 | -86.7 | -75.8 | -134.6 | -109.1 | -156.1 | |
| Capital expenditure | 1.0 | 9.1 | 11.5 | 2.8 | 3.8 | 0.5 | 0.1 | |
| Free cash flow | -51.9 | -78.2 | -98.2 | -78.6 | -138.4 | -109.6 | -156.0 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Stock-based compensation | 5.0 | 13.8 | 17.1 | 19.7 | 26.1 | 22.0 | — |
USD millions · SEC XBRL
4D Molecular Therapeutics, Inc. — questions
- What is 4D Molecular Therapeutics, Inc.'s operating cash flow?
- -$156.1M over the twelve months to 2026-06-30.
- How much does 4D Molecular Therapeutics, Inc. spend on capital expenditure?
- -$106000 over the twelve months to 2026-06-30.
- What is 4D Molecular Therapeutics, Inc.'s free cash flow?
- -$156.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from 4D Molecular Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.